INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Launched by RAND · Apr 22, 2025

Keywords

ClinConnect Summary

The INMIND trial is studying how to help people with HIV stick to their medication plans, which is really important for keeping the virus under control. This study will test a new approach that combines reminders and incentives to help patients take their antiretroviral treatment (ART) regularly. By using a special device called WisePill to track medication adherence, researchers aim to find the best and most cost-effective ways to support long-term adherence to treatment. This trial is taking place in one of the largest HIV clinics in Uganda and hopes to find solutions that can work in other places and for other long-term health conditions.

To participate in this study, you need to be at least 18 years old, have recently started ART, and be able to speak either English or Luganda. You should also have access to a cell phone and be willing to receive daily text messages for six months. Participants will be using the WisePill device to help track their medication use. It’s important to note that people who are not able to give consent or who speak a language other than English or Luganda cannot join the study. If you qualify and decide to participate, you can expect to receive support and encouragement to help you stay on track with your treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female clients age 18 and older.
• • Started ART at Mildmay or another clinic within the preceding 1 month
• • Able to speak and understand either English or Luganda.
• • Have their own cell phone or have consistent access to someone else's phone.
• • Willing to receive daily text messages for the 6 months of intervention duration.
• • Willing and able to use the WisePill device distributed for adherence verification for the duration of the study.
• Exclusion Criteria:
• • Not mentally fit to consent.
• • Language other than Luganda or English.
• • Not willing to consistently use the Wisepill device for adherence measurement.